Hsbc Holdings PLC Buys New Shares in Viridian Therapeutics, Inc. $VRDN

Hsbc Holdings PLC bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 39,452 shares of the company’s stock, valued at approximately $526,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Amalgamated Bank grew its holdings in Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock valued at $34,000 after purchasing an additional 840 shares during the period. SG Americas Securities LLC lifted its position in Viridian Therapeutics by 2.9% during the first quarter. SG Americas Securities LLC now owns 31,972 shares of the company’s stock valued at $431,000 after buying an additional 887 shares in the last quarter. Voya Investment Management LLC lifted its position in Viridian Therapeutics by 5.1% during the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock valued at $410,000 after buying an additional 1,038 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in Viridian Therapeutics by 3.0% during the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock valued at $735,000 after buying an additional 1,106 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC lifted its position in Viridian Therapeutics by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 59,281 shares of the company’s stock valued at $799,000 after buying an additional 1,570 shares in the last quarter.

Wall Street Analysts Forecast Growth

VRDN has been the topic of a number of recent research reports. Needham & Company LLC reduced their price target on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. The Goldman Sachs Group lifted their price target on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, August 7th. JMP Securities reduced their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 7th. Oppenheimer lifted their price target on shares of Viridian Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. Finally, Jefferies Financial Group initiated coverage on shares of Viridian Therapeutics in a research report on Monday, August 25th. They set a “buy” rating and a $44.00 price target on the stock. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $37.78.

Viridian Therapeutics Trading Down 0.3%

NASDAQ VRDN opened at $18.38 on Tuesday. The company’s fifty day simple moving average is $17.01 and its 200-day simple moving average is $15.14. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.50 billion, a P/E ratio of -4.80 and a beta of 0.53.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, hitting analysts’ consensus estimates of ($1.00). Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. During the same period in the previous year, the company posted ($0.81) earnings per share. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. Equities research analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.